The 2021 Genitourinary (GU) Cancers Symposium, one of the largest conference in genitourinary cancers will be held virtually February 11 to 13, showcasing practice-changing research, diverse speakers, global perspectives, and the latest findings in the study, diagnosis, and treatment of GU malignancies.
Here’s what to keep an eye out for:
Phase 3 CLEAR Study: Lenvatinib Plus Pembrolizumab for Advanced Rrenal Cell Carcinoma
Phase 2 CABRAMET trial: Data on Cabozantinib Activity in Brain Metastases in RCC
Adding to the Armamentarium of Therapy for Bladder Cancer
Phase 3 TITAN: Overall Survival Benefit and Safety in Advanced Prostate Cancer
Click here to view the full schedule
